Prior authorization: coverage based on meeting clinical criteria

No explicit prior authorization requirements are stated in this policy excerpt; coverage is determined by whether the requested test meets the clinical coverage criteria and specified intervals.

Prior authorization: none specified in excerpt

There are no separate prior authorization statements in the guideline excerpts provided; follow the policy's clinical coverage criteria for test ordering.

Proprietary panel coverage: panels lack demonstrated clinical utility

Proprietary multi-marker cardiovascular risk panels are listed as commercially available examples but the policy states their clinical utility is lacking and they do not meet coverage criteria for CVD risk assessment.

• Examples include Genova Cardio Check™, Cleveland HeartLab CVD profiles, and other named panels listed in the policy.
• Impact on patient management is unknown and such panels do not meet coverage criteria.

Lipid monitoring frequency for long-term therapy

When monitoring long-term anti-lipid therapy, an annual lipid panel is considered reasonable; CMS guidance also allows up to six measurements in the first year for monitoring dietary or pharmacologic therapy.

• Annual lipid panel usually adequate while on long-term therapy.
• Any single component may be medically necessary up to six times in the first year for monitoring therapy.

Prior authorization: not specified in guideline excerpts

No explicit prior authorization requirements are specified in the cited guideline excerpts; clinicians should follow guideline recommendations and the policy's coverage criteria.

Coding: use listed CPT/HCPCS codes when ordering tests

The policy lists applicable CPT/HCPCS procedure codes for covered tests; providers must use the listed CPT/HCPCS codes when ordering and billing these tests.

• Examples include 80061 (lipid panel), 83695 (Lp[a]), 86141 (hsCRP), and proprietary codes such as 0308U/0309U.
• Use the policy-listed codes on claims and follow any payer-specific prior-authorization rules for proprietary tests.

Prior authorization implications after policy updates

Policy updates changed testing frequencies and supported indications; if an ordered test does not meet the coverage criteria in this policy (for example, tests removed from coverage), prior authorization or claim denial may occur.

• Recent revisions removed allowance for hs-CRP for general screening and clarified Lp(a) frequency (once per lifetime).
• Tests not meeting coverage criteria (e.g., Lp-PLA2, hs-CRP for general screening) may be subject to noncoverage.

CPT code updates: new/revised laboratory codes

Certain CPT/HCPCS laboratory codes were added or revised in recent updates (for example, CPT codes 0308U and 0309U); providers should be aware of these code updates when ordering proprietary or algorithm-based tests.

• Noted updated/added codes include 0308U, 0309U, 0415U, 0541U, and others listed in the revision history and code tables.

Discuss CVD risk and risk-enhancing factors before starting therapy

Clinician-patient risk discussion is recommended prior to initiating pharmacologic preventive therapy; assess risk-enhancing factors to guide decisions about starting statins or other interventions.

• Use 10-year ASCVD risk estimation (PCE) for adults 40–75 and individualize with risk-enhancing factors.
• Discuss benefits and risks of pharmacologic therapy with the patient before initiating treatment.

Therapy thresholds: LDL‑C thresholds by risk category (clinical guidance)

Guidelines describe LDL-C thresholds to guide initiation of pharmacologic LDL-C–lowering therapy by risk category (e.g., very high risk >70 mg/dL; high risk >100 mg/dL), which clinicians should use to inform treatment decisions.

• ESC/EAS guidance: pharmacologic therapy recommended for very high risk with LDL-C >70 mg/dL and high risk with LDL-C >100 mg/dL.
• Consider lower thresholds in selected high-risk categories per guideline statements.

Statin monitoring in renal transplant patients: baseline and 3/12 month transaminases

Measure baseline transaminases before starting statin therapy in renal transplant patients and monitor transaminases at 3 and 12 months after initiation as part of documented therapy monitoring.

• Also measure TC, HDL, and LDL after 3 months aiming for >40% LDL reduction; further monitoring as indicated.

Step therapy: none specified

No step therapy rules are specified in this policy excerpt.

Documentation: record indication, age, and clinical context to support testing

Document the clinical indication (screening vs increased-risk evaluation vs therapy monitoring), patient age, and relevant clinical context (e.g., diabetes, transplant status, HIV on ART) when ordering lipid, apoB, or Lp(a) testing to support medical necessity.

• Include the specific purpose (e.g., baseline before statin, monitoring after therapy change) and applicable guideline-based interval.

Documentation: justify specialized biomarker testing and rationale

When ordering specialized biomarkers (e.g., GlycA, ApoB, Lp[a], hs‑CRP), document the specific indication and rationale for test selection because utility varies by marker and may affect coverage determination.

• Provide rationale tied to clinical scenarios described in the policy (e.g., discordant LDL-C/apoB, family history, premature ASCVD).

Lipid measurement timing: baseline and follow-up around therapy changes

Document baseline fasting lipid panel prior to starting statin therapy and repeat lipid testing 4–12 weeks after initiation or dose change, then every 3–12 months as clinically indicated.

• For persons on ART, obtain fasting lipid profile prior to and within 1–3 months after starting ART and every 6–12 months when stable.

Laboratory reporting: identify extremely elevated LDL‑C and actionable values

Lipid laboratory reports should flag desirable values and specifically identify extremely elevated LDL‑C (≥190 mg/dL) and potentially actionable triglycerides (e.g., TG ≥500 mg/dL).

• Reports should clearly denote severe hypercholesterolemia and report actionable abnormal results.

Recommended timing: measure LDL‑C 4–6 weeks after therapy changes

Measure LDL‑C 4–6 weeks after initiation or intensification of lipid‑lowering therapy to assess response, and document timing and results in the medical record.

• Follow-up lipid measurements thereafter per guideline intervals (e.g., every 3–12 months as clinically indicated).

Required testing documentation: baseline and guideline-based follow-up lipid profiles

Obtain and document baseline and follow-up lipid profiles per guideline-specified intervals (for example, fasting lipid profile prior to and within 1–3 months after starting ART and every 6–12 months if abnormal), and record these in the patient record to support coverage.

• Document adherence, treatment changes, and interval results when used for monitoring therapy or risk reassessment.

Documentation notes: indicate risk factors and frequency limits (e.g., Lp[a] once lifetime)

Document the indication and relevant risk factors when ordering lipid and biomarker testing; note frequency limits such as Lp(a) screening once per lifetime and that Lp(a) measurement should occur after age 18.

• Include supporting clinical details (family history, premature ASCVD, therapy monitoring) to demonstrate medical necessity.

Documentation expectations: record risk‑enhancing factors and quantitative risk assessment

When ordering risk-based tests, document risk‑enhancing factors and the use of a quantitative risk assessment tool (e.g., ACC/AHA Pooled Cohort Equations) to justify testing decisions; Lp(a) testing should be ordered once per lifetime after age 18 when indicated.

• Record the PCE-calculated 10‑year ASCVD risk and any uncertainty prompting adjunct testing.

Denial risk: tests that do not meet coverage criteria and may be denied

Requests for CRP (conventional or high‑sensitivity), hs‑cTnT for outpatient risk stratification, homocysteine, Lp‑PLA2, intermediate density lipoproteins, proprietary multi‑marker panels, and other novel biomarkers for general CVD risk assessment will be denied because they do not meet coverage criteria.

• Do not submit claims for these tests for general CVD risk assessment unless an allowed coverage criterion explicitly applies.

Provider authorization: follow guideline recommendations (no explicit requirements)

There are no explicit provider authorization steps stated in this section; follow the guideline and policy coverage criteria when ordering tests.

Testing frequency implications: document indications for more frequent testing

More frequent testing of total cholesterol, LDL‑C, and triglycerides may be indicated for marked elevations or after therapy changes; without a documented clinical indication, deviations from routine intervals risk noncoverage.

• CMS allows more frequent measurement (up to six times the first year) for therapy monitoring and three times yearly after goals achieved in some situations.

Denial triggers: not specified in this section

Not applicable—the provided excerpts do not list specific payer denial triggers beyond the tests and uses identified as not meeting coverage criteria.

Regulatory conflict resolution: government policy supersedes

If this policy conflicts with applicable government policies (e.g., Medicare LCDs or NCDs), the government policy supersedes and will be used to make coverage determinations.

Denied tests: hs‑CRP and Lp‑PLA2 not supported for general risk assessment

Tests such as hs‑CRP and Lp‑PLA2 were removed or are not supported for cardiovascular disease risk assessment; submitting these for general CVD risk assessment may result in noncoverage or denial.

• hs‑CRP allowance for general screening was removed in the revision history; Lp‑PLA2 is never supported for approval.

CRP/hs‑CRP denials: claims not supported for general screening

Claims for CRP testing (conventional or high‑sensitivity) for general CVD risk assessment are not supported when not described in coverage criteria; removal of prior allowances may lead to denial for broad screening use.

• Policy explicitly states CRP testing DOES NOT MEET COVERAGE CRITERIA for CVD risk assessment.